An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Prof. Nicolas Barry-Delongchamps, Professor of Urology at Cochin Hospital and Principal Investigator of the VIOLETTE trial, will present the final results and one-year patients follow-up from the ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) procedures in Arizona using the Vanquish® Water ...